Your browser doesn't support javascript.
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination.
Hatzakis, Angelos; Karabinis, Andreas; Roussos, Sotirios; Pantazis, Nikos; Degiannis, Dimitrios; Chaidaroglou, Antigoni; Petsios, Konstantinos; Pavlopoulou, Ioanna; Tsiodras, Sotirios; Paraskevis, Dimitrios; Sypsa, Vana; Psichogiou, Mina.
  • Hatzakis A; Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Karabinis A; Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, 115 27 Athens, Greece.
  • Roussos S; Onassis Cardiac Surgery Center, 176 74 Athens, Greece.
  • Pantazis N; Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Degiannis D; Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Chaidaroglou A; Onassis Cardiac Surgery Center, 176 74 Athens, Greece.
  • Petsios K; Onassis Cardiac Surgery Center, 176 74 Athens, Greece.
  • Pavlopoulou I; Onassis Cardiac Surgery Center, 176 74 Athens, Greece.
  • Tsiodras S; Pediatric Research Laboratory, Faculty of Nursing, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Paraskevis D; Fourth Department of Internal Medicine, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Sypsa V; Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
  • Psichogiou M; Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece.
Vaccines (Basel) ; 10(2)2022 Feb 13.
Article in English | MEDLINE | ID: covidwho-1687069
ABSTRACT
Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARS-CoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection against SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The effectiveness (VE) of BNT162b2 in preventing SARS-CoV-2 infection wanes over time, and this reduction is mainly associated with waning immunity, suggesting that the kinetics of antibodies reduction might be of interest to predict VE. In a study of 97 health care workers (HCWs) vaccinated with the BNT162b2 vaccine, we assessed the kinetics of anti-RBD 30-250 days after vaccination using 388 individually matched plasma samples. Anti-RBD levels declined by 85%, 92%, and 95% at the 4th, 6th, and 8th month from the peak, respectively. The kinetics were estimated using the trajectories of anti-RBD by various models. The restricted cubic splines model had a better fit to the observed data. The trajectories of anti-RBD declines were statistically significantly lower for risk factors of severe COVID-19 and the absence of vaccination side effects. Moreover, previous SARS-CoV-2 infection was associated with divergent trajectories consistent with a slower anti-RBD decline over time. These results suggest that anti-RBD may serve as a harbinger for vaccine effectiveness (VE), and it should be explored as a predictor of breakthrough infections and VE.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020285

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10020285